Immunotherapy of bladder cancer targeting P53.

[1]  J. Patard,et al.  An antigen recognized by autologous CTLs on a human bladder carcinoma. , 1998, Journal of immunology.

[2]  D. Diamond,et al.  Targeting p53 for adoptive T-cell immunotherapy. , 1998, Cancer research.

[3]  Taylor Murray,et al.  Cancer statistics, 1998 , 1998, CA: a cancer journal for clinicians.

[4]  J. York,et al.  Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. , 1997, Blood.

[5]  G. Fleuren,et al.  Tumor Eradication by Wild-type p53-specific Cytotoxic T Lymphocytes , 1997, The Journal of experimental medicine.

[6]  K. Steven,et al.  Long-term efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ: relationship of progression to histological response and p53 nuclear accumulation. , 1997, The Journal of urology.

[7]  D. Diamond,et al.  The use of transgenic mice to generate high affinity p53 specific cytolytic T cells. , 1997, The Journal of surgical research.

[8]  L. Fugger,et al.  Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[9]  S. Kudo,et al.  Detection of circulating anti-p53 antibodies in patients with colorectal carcinoma and the antibody's relation to clinical factors , 1996, Diseases of the colon and rectum.

[10]  T. Soussi.  The humoral response to the tumor-suppressor gene-product p53 in human cancer: implications for diagnosis and therapy. , 1996, Immunology today.

[11]  R. Kaempfer,et al.  Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  E. Paoletti,et al.  p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[13]  L. Howell,et al.  Relationship of p53 and bcl-2 to prognosis in muscle-invasive transitional cell carcinoma of the bladder. , 1996, The Journal of urology.

[14]  H. Sakamoto,et al.  Therapy of murine tumors with p53 wild-type and mutant sequence peptide- based vaccines , 1996, The Journal of experimental medicine.

[15]  D. Schaid,et al.  Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[16]  N. Vogelzang.  Comprehensive Textbook of Genitourinary Oncology , 1996 .

[17]  S. Syrjänen,et al.  Implications of the p53 tumor-suppressor gene in clinical oncology. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  S C Chen,et al.  Accumulation of nuclear p53 and tumor progression in bladder cancer. , 1994, The New England journal of medicine.

[19]  Y. Tomita,et al.  mRNA and protein expression of p53 mutations in human bladder cancer cell lines. , 1994, Cancer letters.

[20]  S. H. van der Burg,et al.  p53, a potential target for tumor-directed T cells. , 1994, Immunology letters.

[21]  T. Soussi,et al.  Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. , 1994, British Journal of Cancer.

[22]  R. Cote,et al.  Two molecular pathways to transitional cell carcinoma of the bladder. , 1994, Cancer research.

[23]  S. H. van der Burg,et al.  In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild‐type p53 , 1993, European journal of immunology.

[24]  S. H. van der Burg,et al.  Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides. , 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[25]  Bert Vogelstein,et al.  p53 function and dysfunction , 1992, Cell.

[26]  J. Whitton,et al.  A common antiviral cytotoxic T-lymphocyte epitope for diverse major histocompatibility complex haplotypes: implications for vaccination. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[27]  M. Oren,et al.  Wild-type p53 can inhibit oncogene-mediated focus formation. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[28]  A. Levine,et al.  The p53 proto-oncogene can act as a suppressor of transformation , 1989, Cell.

[29]  Brosman Sa.  The influence of Tice strain BCG treatment in patients with transitional cell carcinoma in situ. , 1989 .

[30]  A. Levine,et al.  Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life , 1988, Molecular and cellular biology.

[31]  T. Ahlering,et al.  A new in vivo model to study invasion and metastasis of human bladder carcinoma. , 1987, Cancer research.

[32]  P. Jones,et al.  Growth of normal and neoplastic urothelium and response to epidermal growth factor in a defined serum-free medium. , 1987, Cancer research.

[33]  W. Catalona,et al.  Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. , 1987, The Journal of urology.

[34]  P. Cresswell,et al.  Impaired assembly and transport of HLA‐A and ‐B antigens in a mutant TxB cell hybrid. , 1986, The EMBO journal.

[35]  Y. Ohnuki,et al.  Ultrastructure, karyology and immunology of a cell line originated from a human transitional-cell carcinoma. , 1978, British Journal of Cancer.

[36]  T. Orfeo,et al.  One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. , 1977, Journal of the National Cancer Institute.